カテゴリ： GlobalData, アメリカ, 企業調査

Athenex Inc (ATNX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8011818
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月13日
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation and clinical development. It offers products such as ointment formulation, oral formulation, oral absorption platform and symptom therapeutics. Athenex also provides transmucosal drug, active ingredients and intermediates, pharmaceutical and specialty chemicals, and in-vitro diagnostic devices. The company has its presence in the US and China. It partners with pharmaceutical companies, universities and research institutions located across Guangzhou, China; Dunedin, New Zealand; Taipei, Taiwan; Seoul, South Korea; and Guatemala City, Guatemala. Athenex is headquartered in Buffalo, New York, the US.

Athenex Inc (ATNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Athenex Inc, Medical Devices Deals, 2011 to YTD 2017 12
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Athenex Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 15
Venture Financing 16
Athenex Raises USD20 Million in Venture Debt Financing 16
Athenex Raises USD38 Million in Financing 17
Kinex Pharma Raises USD10 Million in Venture Financing 18
Kinex Pharma Raises USD74.4 Million in Venture Financing 19
Kinex Pharma Raises US$0.3 Million In Venture Financing 20
QuaDPharma Raises US$1 Million In Venture Financing 21
Kinex Pharma Raises Funds In First Tranche Of Financing Round 22
Kinex Pharma Raises US$5 Million In Venture Financing 23
Partnerships 24
Athenex Enters into Agreement with Imuna Pharm 24
Athenex Enters into Partnership with Eli Lilly and Company 25
Athenex to Form Joint Venture with SunGen Pharma 26
Licensing Agreements 27
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 27
Athenex to Enter into Licensing Agreement with Gland Pharma 28
Athenex to Enter into Licensing Agreement with Gland Pharma 29
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 30
PharmaEssentia Amends its Licensing Agreement with Athenex for Oraxol and Oratecan 31
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 32
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 33
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 34
PharmaEssentia Amends its Licensing Agreement with Kinex Pharma 35
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 37
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 38
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 40
Equity Offering 42
Athenex Raises USD76 Million in IPO 42
Athenex Raises USD3.5 Million in Private Placement of Shares 44
Athenex Raises USD5 Million in Private Placement of Shares 45
Athenex Raises USD6.6 Million in Private Placement of Shares 46
Kinex Pharma Raises Funds through Private Placement of Shares 47
Athenex Raises USD4 Million in Private Placement of Shares 48
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 49
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 50
Acquisition 51
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 51
Athenex Acquires Polymed Therapeutics 52
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 53
Athenex Inc – Key Competitors 54
Athenex Inc – Key Employees 55
Athenex Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Strategy And Business Planning 57
Feb 11, 2016: Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York 57
Financial Announcements 60
Nov 09, 2017: Athenex Announces Third Quarter 2017 Results 60
Aug 14, 2017: Athenex Announces Second Quarter 2017 Results 63
Corporate Communications 66
Dec 01, 2017: Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle 66
Mar 01, 2017: Athenex announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer 67
Feb 27, 2017: Athenex appoints veteran J. Nick Riehle as Chief Financial Officer 68
Feb 09, 2016: Athenex Announces the Addition of Simon Pedder, PhD and Raymond Yeung, MSc, MBA to its Global Leadership Team 69
Government and Public Interest 70
Sep 11, 2017: Athenex Announces Grant Disbursement Agreement with New York State for Dunkirk Facility 70
Product News 71
Aug 01, 2017: Athenex Announces Recent Product Launches in Commercial Business 71
Clinical Trials 72
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting 72
Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis 73
Mar 28, 2017: Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Athenex Inc, Pharmaceuticals & Healthcare, Key Facts 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Athenex Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Athenex Inc, Medical Devices Deals, 2011 to YTD 2017 12
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 15
Athenex Raises USD20 Million in Venture Debt Financing 16
Athenex Raises USD38 Million in Financing 17
Kinex Pharma Raises USD10 Million in Venture Financing 18
Kinex Pharma Raises USD74.4 Million in Venture Financing 19
Kinex Pharma Raises US$0.3 Million In Venture Financing 20
QuaDPharma Raises US$1 Million In Venture Financing 21
Kinex Pharma Raises Funds In First Tranche Of Financing Round 22
Kinex Pharma Raises US$5 Million In Venture Financing 23
Athenex Enters into Agreement with Imuna Pharm 24
Athenex Enters into Partnership with Eli Lilly and Company 25
Athenex to Form Joint Venture with SunGen Pharma 26
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 27
Athenex to Enter into Licensing Agreement with Gland Pharma 28
Athenex to Enter into Licensing Agreement with Gland Pharma 29
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 30
PharmaEssentia Amends its Licensing Agreement with Athenex for Oraxol and Oratecan 31
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 32
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 33
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 34
PharmaEssentia Amends its Licensing Agreement with Kinex Pharma 35
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 37
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 38
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 40
Athenex Raises USD76 Million in IPO 42
Athenex Raises USD3.5 Million in Private Placement of Shares 44
Athenex Raises USD5 Million in Private Placement of Shares 45
Athenex Raises USD6.6 Million in Private Placement of Shares 46
Kinex Pharma Raises Funds through Private Placement of Shares 47
Athenex Raises USD4 Million in Private Placement of Shares 48
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 49
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 50
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 51
Athenex Acquires Polymed Therapeutics 52
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 53
Athenex Inc, Key Competitors 54
Athenex Inc, Key Employees 55
Athenex Inc, Subsidiaries 56

★海外企業調査レポート[Athenex Inc (ATNX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chiyoda Corp (6366)：企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Nationwide Financial Services, Inc.：企業の戦略的SWOT分析
    Nationwide Financial Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Chico’s FAS Inc：戦略・SWOT・企業財務分析
    Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report Summary Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • QEP Resources Inc (QEP)：石油・ガス：M&Aディール及び事業提携情報
    Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southern Region essentially in Texas and Louisiana. In Northern Region, the company owns productive w …
  • NW Natural Gas Co：企業の戦略的SWOT分析
    NW Natural Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ResApp Health Ltd (RAP)：製薬・医療：M&Aディール及び事業提携情報
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Koito Manufacturing Co Ltd：企業の戦略・SWOT・財務情報
    Koito Manufacturing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Koito Manufacturing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Myriad Genetics Inc (MYGN)：企業の財務・戦略的SWOT分析
    Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Namibia Breweries Limited：戦略・SWOT・企業財務分析
    Namibia Breweries Limited - Strategy, SWOT and Corporate Finance Report Summary Namibia Breweries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Senetas Corporation Limited：企業の戦略・SWOT・財務情報
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Thermalin Diabetes LLC-製薬・医療分野：企業M&A・提携分析
    Summary Thermalin Diabetes LLC (Thermalin) is an insulin analogs developer. The company develops concentrated insulin analog for the treatment of individuals with insulin resistance and for use in miniature insulin pumps. It develops both molecular and formulation strategies to produce an acting ana …
  • Enanta Pharmaceuticals Inc (ENTA)：企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • Abbott India Ltd (ABBOTINDIA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Abbott India Ltd (Abbott India), a subsidiary of Abbott Laboratories discovers, develops, manufactures and markets branded generic pharmaceuticals, diagnostics tools, medical devices and nutritionals. Its product portfolio encompasses multi-specialty drugs, vitamins and a comprehensive range …
  • Mallinckrodt plc：企業の戦略・SWOT・財務情報
    Mallinckrodt plc - Strategy, SWOT and Corporate Finance Report Summary Mallinckrodt plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Abu Dhabi Investment Authority：電力：M&Aディール及び事業提携情報
    Summary Abu Dhabi Investment Authority (ADIA) is a sovereign wealth fund owned and managed by Emirate of Abu Dhabi. It invests directly in global financial markets along with trusted partner’s selected external managers. The company’s investment portfolio includes developed equities, small cap equit …
  • Epax Norway AS：企業の戦略・SWOT・財務情報
    Epax Norway AS - Strategy, SWOT and Corporate Finance Report Summary Epax Norway AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • China UnionPay Co Ltd：企業の戦略・SWOT・財務分析
    China UnionPay Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China UnionPay Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Spark New Zealand Ltd：企業の戦略・SWOT・財務分析
    Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report Summary Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Camurus AB (CAMX)：企業の財務・戦略的SWOT分析
    Summary Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s technology includes smart and versatile drug delivery, injection depot, …
  • Smiths Group plc：戦略・SWOT・企業財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆